{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:09:26Z","timestamp":1780103366957,"version":"3.54.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Urol Int"],"published-print":{"date-parts":[[2011]]},"abstract":"<jats:p>&lt;i&gt;Purpose:&lt;\/i&gt; To report our experience with temsirolimus in 2nd-, 3rd- and 4th-line therapy for patients with metastatic renal cell carcinoma (mRCC). &lt;i&gt;Patients and Methods:&lt;\/i&gt; In our prospectively maintained tumor registry, we identified 6 mRCC patients with temsirolimus in &gt;1st-line systemic therapy. Patients were followed by weekly clinical and laboratory examination during admission of temsirolimus. Re-staging with chest CT and abdominal MRI was performed every 3 months. &lt;i&gt;Results:&lt;\/i&gt; We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, pneumonitis was observed in 4 of 6 patients. Drug-related pneumonitis led to severe dyspnea, with the result that treatment with temsirolimus had to be interrupted for a short period of time in 2 patients and discontinued in 1 patient. &lt;i&gt;Conclusions:&lt;\/i&gt; Temsirolimus proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of pneumonitis must not be underestimated.<\/jats:p>","DOI":"10.1159\/000322545","type":"journal-article","created":{"date-parts":[[2011,4,19]],"date-time":"2011-04-19T10:36:45Z","timestamp":1303209405000},"page":"256-260","source":"Crossref","is-referenced-by-count":7,"title":["Initial Experience with Temsirolimus in 2nd-, 3rd- and 4th-Line Therapy for Metastatic Renal Cell Cancer: Good Clinical Response"],"prefix":"10.1159","volume":"86","author":[{"given":"Timur Hasan","family":"Kuru","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gencay","family":"Hatiboglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Wagener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Pahernik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Hadaschik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hohenfellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2011,1,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.eururo.2010.06.032"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa066838"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdn066"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.20.1.289"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ejca.2008.10.026"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.urology.2009.12.031"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.25219"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.ejca.2006.03.015"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097%2FCAD.0b013e32833760bf"}],"container-title":["Urologia Internationalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322545","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/322545","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T19:12:00Z","timestamp":1745435520000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000322545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2011,4,1]]},"published-print":{"date-parts":[[2011,4,20]]}},"URL":"https:\/\/doi.org\/10.1159\/000322545","archive":["Portico"],"relation":{},"ISSN":["0042-1138","1423-0399"],"issn-type":[{"value":"0042-1138","type":"print"},{"value":"1423-0399","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}